Clinical pharmacokinetics of topotecan
VMM Herben, WW ten Bokkel Huinink… - Clinical …, 1996 - Springer
Topotecan (Hycamtin®), a semisynthetic water-soluble derivative of camptothecin, is a potent
inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging antitumour …
inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging antitumour …
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
VMM Herben, JH Beijnen… - Pharmacy World and …, 1998 - Springer
In this review the clinical pharmacokinetics of camptothecin topoisomerase I inhibitors, an
important new class of anticancer drugs, is discussed. Two prototypes, topotecan and …
important new class of anticancer drugs, is discussed. Two prototypes, topotecan and …
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
…, A Wennerholm, J Eriksen, VMM Herben… - Pharmacogenetics …, 2006 - journals.lww.com
Objectives To study the correlation between CYP3A5 genotype and quinine 3-hydroxylation
in black Tanzanian and Swedish Caucasians as well as to investigate the interethnic …
in black Tanzanian and Swedish Caucasians as well as to investigate the interethnic …
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and α-OH-midazolam
B Tuk, MF Van Oostenbruggen, VMM Herben… - … of Pharmacology and …, 1999 - ASPET
The pharmacodynamic interaction between midazolam and its active metabolite α-OH-midazolam
was investigated to evaluate whether estimates of relevant pharmacodynamic …
was investigated to evaluate whether estimates of relevant pharmacodynamic …
Oral topotecan: bioavailability and effect of food co-administration
VMM Herben, H Rosing, WW Huinink… - British journal of …, 1999 - nature.com
The aims of the study were twofold:(1) to evaluate the effect of food on the relative oral
bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine …
bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine …
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
VMM Herben, JHM Schellens, M Swart… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To evaluate the feasibility of administering irinotecan as a continuous
intravenous infusion for 14 to 21 days. PATIENTS AND METHODS: Patients with solid tumors …
intravenous infusion for 14 to 21 days. PATIENTS AND METHODS: Patients with solid tumors …
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
VMM Herben, WW ten Bokkel Huinink… - British journal of …, 1997 - nature.com
We performed a phase I and pharmacological study to determine the maximum tolerated dose
(MTD) and dose-limiting toxicities (DLT) of a cytotoxic regimen of the novel topoisomerase …
(MTD) and dose-limiting toxicities (DLT) of a cytotoxic regimen of the novel topoisomerase …
Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam
B Tuk, VMM Herben, JW Mandema, M Danhof - Journal of Pharmacology …, 1998 - ASPET
In the present investigation, the extent of arteriovenous concentration differences of
midazolam in rats was quantified, and the consequences of these differences on the …
midazolam in rats was quantified, and the consequences of these differences on the …
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients …
VMM Herben, VR Nannan Panday… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel
and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as …
and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as …
Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan
H Rosing, VMM Herben, DMG Zomeren, E Hop… - Cancer chemotherapy …, 1997 - Springer
A sensitive high-performance liquid chromatography (HPLC) method for the determination
of topotecan and total levels of topotecan (lactone plus its ring-opened hydroxycarboxylate …
of topotecan and total levels of topotecan (lactone plus its ring-opened hydroxycarboxylate …